Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
27
10
2021
accepted:
12
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
28
4
2022
Statut:
epublish
Résumé
Recently accumulating evidence suggests the pivotal role of type 1 interferon (IFN-1) signature in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). However, the mechanism of the initial trigger that augments IFN-1 pathway in the peripheral immune system of NMOSD has yet to be elucidated. Clinical samples were obtained from 32 patients with aquaporin-4 antibody-positive NMOSD and 23 healthy subjects. IFN-1 induction in peripheral blood mononuclear cells (PBMCs) by serum-derived cell-free DNA (cfDNA) was assessed in combination with blockades of DNA sensors in vitro. CfDNA fraction was analyzed for DNA methylation profiles by bisulfite sequencing, elucidating the cellular origin of cfDNA. The induction of neutrophil extracellular trap related cell death (NETosis) was further analyzed in NMOSD and control groups, and the efficacy of pharmacologic intervention of NETosis was assessed. Enhanced IFN-1 induction by cfDNA derived from NMOSD was observed in PBMCs with cofactor of LL37 antimicrobial peptide. DNase treatment, cGAS inhibitor, and Toll-like receptor 9 antagonist efficiently inhibited IFN-1 production. DNA methylation pattern of cfDNA in patients with NMOSD demonstrated that the predominant cellular source of cfDNA was neutrophils. Whole blood transcriptome analysis also revealed neutrophil activation in NMOSD. In addition, enhanced NETosis induction was observed with NMOSD-derived sera, and efficient pharmacologic inhibition of NETosis with dipyridamole was observed. Our study highlights the previously unrevealed role of cfDNA predominantly released by neutrophil in the induction of IFN-1 signature in NMOSD and further indicate a novel pharmacologic target in NMOSD.
Sections du résumé
BACKGROUND AND OBJECTIVES
Recently accumulating evidence suggests the pivotal role of type 1 interferon (IFN-1) signature in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). However, the mechanism of the initial trigger that augments IFN-1 pathway in the peripheral immune system of NMOSD has yet to be elucidated.
METHODS
Clinical samples were obtained from 32 patients with aquaporin-4 antibody-positive NMOSD and 23 healthy subjects. IFN-1 induction in peripheral blood mononuclear cells (PBMCs) by serum-derived cell-free DNA (cfDNA) was assessed in combination with blockades of DNA sensors in vitro. CfDNA fraction was analyzed for DNA methylation profiles by bisulfite sequencing, elucidating the cellular origin of cfDNA. The induction of neutrophil extracellular trap related cell death (NETosis) was further analyzed in NMOSD and control groups, and the efficacy of pharmacologic intervention of NETosis was assessed.
RESULTS
Enhanced IFN-1 induction by cfDNA derived from NMOSD was observed in PBMCs with cofactor of LL37 antimicrobial peptide. DNase treatment, cGAS inhibitor, and Toll-like receptor 9 antagonist efficiently inhibited IFN-1 production. DNA methylation pattern of cfDNA in patients with NMOSD demonstrated that the predominant cellular source of cfDNA was neutrophils. Whole blood transcriptome analysis also revealed neutrophil activation in NMOSD. In addition, enhanced NETosis induction was observed with NMOSD-derived sera, and efficient pharmacologic inhibition of NETosis with dipyridamole was observed.
DISCUSSION
Our study highlights the previously unrevealed role of cfDNA predominantly released by neutrophil in the induction of IFN-1 signature in NMOSD and further indicate a novel pharmacologic target in NMOSD.
Identifiants
pubmed: 35210295
pii: 9/3/e1149
doi: 10.1212/NXI.0000000000001149
pmc: PMC8874356
pii:
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Interferons
9008-11-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Nature. 2007 Oct 4;449(7162):564-9
pubmed: 17873860
BMC Neurol. 2016 Jul 11;16:96
pubmed: 27401736
Nat Med. 2016 Feb;22(2):146-53
pubmed: 26779811
PLoS One. 2012;7(10):e48111
pubmed: 23110185
Arch Neurol. 2010 Aug;67(8):1016-7
pubmed: 20697055
Sci Transl Med. 2013 Mar 27;5(178):178ra40
pubmed: 23536012
J Immunol. 2016 Jan 1;196(1):91-6
pubmed: 26590315
Front Immunol. 2021 Jul 29;12:703931
pubmed: 34394101
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):E5302-11
pubmed: 25427797
Immunol Cell Biol. 2012 May;90(5):498-504
pubmed: 22430248
BMC Bioinformatics. 2018 Dec 19;19(1):534
pubmed: 30567491
Nat Commun. 2020 Jun 5;11(1):2856
pubmed: 32503977
Nat Commun. 2018 Nov 29;9(1):5068
pubmed: 30498206
Clin Dev Immunol. 2013;2013:713519
pubmed: 24348680
Eur J Neurol. 2010 May;17(5):672-6
pubmed: 20039942
Curr Protoc Immunol. 2015 Nov 02;111:7.23.1-7.23.16
pubmed: 26528633
Nat Commun. 2019 Apr 23;10(1):1916
pubmed: 31015489
Mult Scler. 2012 Oct;18(10):1480-3
pubmed: 22354738
Immunity. 2016 Mar 15;44(3):683-697
pubmed: 26968426
Ann Rheum Dis. 2018 Oct;77(10):1507-1515
pubmed: 29945921
Neurology. 2010 Oct 19;75(16):1423-7
pubmed: 20826711
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Blood. 2012 Nov 1;120(18):3699-707
pubmed: 22927244
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Front Immunol. 2019 Mar 19;10:502
pubmed: 30941136
Mod Rheumatol. 2021 Jan;31(1):1-12
pubmed: 32814461
Sci Transl Med. 2011 Mar 9;3(73):73ra19
pubmed: 21389263
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
FEBS Lett. 2010 Jul 16;584(14):3193-7
pubmed: 20541553
J Clin Invest. 2012 Jul;122(7):2661-71
pubmed: 22684106
Mult Scler. 2012 Apr;18(4):398-408
pubmed: 22343184
Ann Rheum Dis. 2017 Aug;76(8):1440-1448
pubmed: 28416516